Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, YK11 was found to promote osteoblast cell proliferation and differentiation through activation of non-genomic signaling pathways in mouse osteoblast cells.

This study found that most potassium channel blockers increased the activity of slowly adapting mechanoreceptors in rat whisker pads, while the opener NS1619 decreased their evoked activity.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

This study developed and validated a sensitive liquid chromatography–mass spectrometry method to measure aristolochic acid‐I in rat plasma, successfully applying it to pharmacokinetic research.

In this animal study, the researchers found that administering anionic lipid nanoemulsions called squarticles increased survival rates and mitigated the adverse effects of amitriptyline overdose in rats.

This article reviews current understanding and management of peripheral arterial disease and reports no new results; the authors emphasize early diagnosis and lifestyle modification for better outcomes.

This study found that the film-trigger applicator system enhanced drug delivery efficiency and skin penetration of dissolving microneedles compared to traditional patch systems in both lab and animal models.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

In this study, researchers using Arabidopsis thaliana found that adenosine may inhibit root hair growth and stomatal opening, suggesting it plays a signaling role in plants similar to its function in animal cells, potentially revealing a new adenosine-like receptor pathway.

This study found that precision 40Hz gamma-transcranial alternating current stimulation significantly improved negative and cognitive symptoms in patients with schizophrenia compared to a sham group, suggesting promising potential for this neuromodulation technique in treating these symptoms.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study estimates that adding baricitinib to a commercial formulary for treating severe alopecia areata would slightly increase the budget by $1,383,345 over five years, with minimal impact per member per month.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

In this study, researchers developed a new method for producing dissolving microneedle array patches containing mesoporous silica nanoparticles, successfully confirming nanoparticle deposition and release in both ex vivo and in vivo models.

This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.